Immix Biopharma publishes corporate presentation on NXC-201 BCMA CAR-T in relapsed/refractory AL amyloidosis
Reuters2026/08/10 19:31- Immix highlighted NXC-201, a BCMA-targeted CAR-T, as its lead program for relapsed or refractory AL amyloidosis.
- NEXICART-2 U.S. open-label single-arm phase 1/2 trial enrollment completed at 45 patients; primary efficacy measure is complete hematologic response.
- Presentation cited a 95% complete response rate for NXC-201, versus 0-10% complete response rates reported for investigator’s-choice regimens.
- Company outlined a planned BLA submission following 1-year follow-up for all 45 patients; next trial update targeted for late September 2026.
- Commercial launch plan targets end of 2027; pricing reference cited USD 588,000 for 2026 Carvykti BCMA CAR-T.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
US Dollar: Range-bound support as Fed priced – ING
GBP/JPY Price Forecast: Six-month lows at the 209.20 area under pressure
Temple Bar Investment Trust Sept. 4 estimated NAV with debt at par value at 413.32 pence/share
The yield on the 10-year US Treasury is approaching the 5.5% red line! Societe Generale warns: Stock valuation support is failing, US stocks may face a severe shock.
Société Générale pointed out that this year’s global profit expectations have been significantly raised. Even with rising yields, this has prevented equity risk premiums from plunging.
Crypto prices
More
